Evidence map›Paper›PMID 25547790›Full record

ArticleInfection and immunity2015

Nonbinding site-directed mutants of transferrin binding protein B exhibit enhanced immunogenicity and protective capabilities.

Rafael Frandoloso, Sonia Martínez-Martínez, Charles Calmettes, Jamie Fegan, Estela Costa, Dave Curran, Rong-Hua Yu, César B Gutiérrez-Martín, Elías F Rodríguez-Ferri, Trevor F Moraes and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Infection and immunity, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
4.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 60 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. TbpBPathogens (Basel, Switzerland) · 2022
    Article
  13. Stealthy microbes: HowFrontiers in cellular and infection microbiology · 2022
    Review
  14. Article
  15. Recent Progress Towards a Gonococcal Vaccine.Frontiers in cellular and infection microbiology · 2022
    Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 3 countries.

Rafael FrandolosoLaboratory of Immunology, Faculty of Agronomy and Veterinary Medicine, University of Passo Fundo, São José, Passo Fundo, Brazil Department of Animal Health, University of León, León, Spain.
Sonia Martínez-MartínezDepartment of Animal Health, University of León, León, Spain.
Charles CalmettesDepartment of Biochemistry, University of Toronto, Toronto, Canada.
Jamie FeganDepartment of Microbiology, Immunology, and Infectious Diseases, University of Calgary, Calgary, Canada.
Estela CostaDepartment of Microbiology, Immunology, and Infectious Diseases, University of Calgary, Calgary, Canada.
Dave CurranDepartment of Microbiology, Immunology, and Infectious Diseases, University of Calgary, Calgary, Canada.
Rong-Hua YuDepartment of Microbiology, Immunology, and Infectious Diseases, University of Calgary, Calgary, Canada.
César B Gutiérrez-MartínDepartment of Animal Health, University of León, León, Spain.
Elías F Rodríguez-FerriDepartment of Animal Health, University of León, León, Spain.
Trevor F MoraesDepartment of Biochemistry, University of Toronto, Toronto, Canada.
Anthony B SchryversDepartment of Microbiology, Immunology, and Infectious Diseases, University of Calgary, Calgary, Canada schryver@ucalgary.ca.
University of Calgary · CAUniversidad de León · ESUniversity of Toronto · CAUniversidade de Passo Fundo · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Host-adapted Gram-negative bacterial pathogens from the Pasteurellaceae, Neisseriaceae, and Moraxellaceae families normally reside in the upper respiratory or genitourinary tracts of their hosts and rely on utilizing iron from host transferrin (Tf) for growth and survival. The surface receptor proteins that mediate this critical iron acquisition pathway have been proposed as ideal vaccine targets due to the critical role that they play in survival and disease pathogenesis in vivo. In particular, the surface lipoprotein component of the receptor, Tf binding protein B (TbpB), had received considerable attention as a potential antigen for vaccines in humans and food production animals but this has not translated into the series of successful vaccine products originally envisioned. Preliminary immunization experiments suggesting that host Tf could interfere with development of the immune response prompted us to directly address this question with site-directed mutant proteins defective in binding Tf. Site-directed mutants with dramatically reduced binding of porcine transferrin and nearly identical structure to the native proteins were prepared. A mutant Haemophilus parasuis TbpB was shown to induce an enhanced B-cell and T-cell response in pigs relative to native TbpB and provide superior protection from infection than the native TbpB or a commercial vaccine product. The results indicate that binding of host transferrin modulates the development of the immune response against TbpBs and that strategies designed to reduce or eliminate binding can be used to generate superior antigens for vaccines.

Indexed as

AnimalsAntibodies, BacterialB-LymphocytesGene ExpressionHaemophilus InfectionsHaemophilus parasuisHaemophilus VaccinesImmunity, CellularImmunity, HumoralImmunoglobulin MIronMutagenesis, Site-DirectedRecombinant ProteinsSwineT-LymphocytesTransferrinAntibodies, BacterialHaemophilus VaccinesImmunoglobulin MIronRecombinant ProteinsTransferrinTransferrin-Binding Protein B

Identifiers

PMID25547790
PMCPMC4333475
OpenAlexW2155864303

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.